A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 65
Summary
- Conditions
- Colorectal Cancer
- Acral Lentiginous Melanoma
- Breast Cancer
- DMMR Colorectal Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Melanoma
- Urothelial Carcinoma
- MSI-H Colorectal Cancer
- Non -Small Cell Lung Cancer
- Ovarian Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
For the ATRC-101 monotherapy cohorts, enrollment is restricted to adults with breast cancer (BC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer, and acral melanoma. For the pembrolizumab combination therapy cohort, enrollment is restricted to adults with NSCLC, CRC (onl...
For the ATRC-101 monotherapy cohorts, enrollment is restricted to adults with breast cancer (BC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer, and acral melanoma. For the pembrolizumab combination therapy cohort, enrollment is restricted to adults with NSCLC, CRC (only MSI-H or dMMR), melanoma (with the exception of uveal melanoma), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), or urothelial carcinoma (UC), that have been treated with pembrolizumab and have progressed or have achieved stable disease and who, in the judgment of their treating physicians, could benefit from the addition of ATRC-101 to improve or maintain their response.
Tracking Information
- NCT #
- NCT04244552
- Collaborators
- Not Provided
- Investigators
- Study Director: Jonathan Benjamin, MD, PhD Atreca, Inc.
Get Well Soon